Key result
The 2022 ESC Guidelines recommend measuring high-sensitivity cardiac troponin before and after intermediate- and high-risk non-cardiac surgery in patients with cardiovascular risk factors.
Answers are grounded in this paper and cite their sources.
Routine measurement of hs-cTn T/I before intermediate- and high-risk non-cardiac surgery is recommended to improve risk stratification and detect peri-operative myocardial injury.
This commentary refers to ‘2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery’, by S. Halvorsen et al., https://doi.org/10.1093/eurheartj/ehac270 and the discussion piece ‘Routine troponin testing before non-cardiac surgery: does the evidence justify the consequences?’, by Y. Ben-Baruch Golan and D. Zahger, https://doi.org/10.1093/eurheartj/ehad227. We thank Golan and Zagher for their interest in the 2022 European Society of Cardiology (ESC) Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery (NCS).1 The 2022 ESC Guidelines highlight that the majority of patients undergoing NCS do have a very low risk of cardiac complications and do therefore not require additional testing as part of their risk stratification and/or monitoring. In addition, the 2022 ESC Guidelines recommend to measure high-sensitivity cardiac troponin T or I (hs-cTn T/I) before intermediate- and high-risk NCS, and at 24 and 48 h afterwards, in patients who have known cardiovascular (CV) disease, CV risk factors (including age ≥65 years), or symptoms suggestive of CV disease (Class I LoE B).1 The main roles of hs-cTn T/I concentrations pre-operatively, are (i) to increase the accuracy of pre-operative risk assessment for peri-operative CV complications, facilitating informed decision making for physicians and patients regarding the risk–benefit ratio of the planned surgery, and (ii) to reliably detect peri-operative myocardial infarction/injury (PMI), a silent and neglected killer following NCS, frequently asymptomatic or oligosymptomatic and therefore requiring active surveillance. A third role is to help in the detection of undiagnosed or underestimated cardiac disease; this role is similar to the non-surgical setting, and is not the topic of our guideline. Several prospective studies have shown that hs-cTn T/I adds to clinical risk estimation tools pre-operatively, and also have prognostic value in itself.2,3 The guideline-recommended measurement of hs-cTn T/I before intermediate- or high-risk NCS helps in identifying patients at high risk of peri-operative CV complications, and high hs-cTn T/I concentrations should be used as a trigger for optimisation of treatment of CV risk factors/CV disease, and for further cardiac work-up if needed. Elevated hs-cTn T/I concentrations pre-operatively may also provide an argument for intensified peri- and post-operative monitoring. Furthermore, better risk stratification provides the opportunity to give patients more accurate information about the risks, facilitating the decision about surgery. Irrespective of the cause, patients with PMIs have been shown to have an impaired long-term prognosis.4 It is therefore important that PMIs are detected early so clinicians can start promptly to look for treatable causes, and also to decide the further levels of care (e.g. prolongation of stay at the intensive care unit and closer follow-up). Golan and Zagher comment on the Figure 12 of the guideline.1 The initial steps in management of patients with chronic coronary syndromes scheduled for intermediate- or high-risk NCS are the same as the general recommendations: clinical examination, electrocardiogram (ECG), and biomarkers (Class I), as well as assessment of functional capacity (Class IIa). In those with abnormal findings in these first steps, the next step would be non-invasive imaging with transthoracal echocardiography +/− stress imaging. A last step consisting of invasive coronary angiography is suggested in those in whom the integrated clinical judgment of all information at that time point suggests a high likelihood for a large area of ischaemia or an unstable clinical condition. We agree with Golan and Zagher that Figure 12 could have been clearer about the indications for this last step. All authors declare no funding for this contribution.
No takes yet. Share an insight, caveat, or question.
Halvorsen et al. (2023) conducted an editorial in Patients undergoing non-cardiac surgery. High-sensitivity cardiac troponin testing was evaluated. The 2022 ESC Guidelines recommend measuring high-sensitivity cardiac troponin before and after intermediate- and high-risk non-cardiac surgery in patients with cardiovascular risk factors.
Synapse has enriched 10 related papers. Consider them for comparative context: